WCM
CCXI

Wedge Capital Management’s ChemoCentryx, Inc. CCXI Stock Holding History

Wedge Capital Management’s Portfolio CCXI Stock Details CCXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-45,300
Closed -$424K – 594
2017
Q2 		$424K Buy
+45,300
New +$333K ﹤0.01% 463

Other funds holding CCXI

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wedge Capital Management's CCXI Position: Q3 2017 in Review

Wedge Capital Management sold out of ChemoCentryx, Inc. (CCXI) in Q3 2017, closing a stake of 45,300 shares — an estimated $424K sold.

Wedge Capital Management first reported a position in CCXI in Q2 2017 and held it in 1 quarter. The position peaked at $424K in Q2 2017. 86 funds tracked by Wall St. Rank hold CCXI as of Q3 2017.

  • Wedge Capital Management reported no remaining ChemoCentryx, Inc. position as of Q3 2017 after selling out during the quarter.
  • Wedge Capital Management sold 45,300 ChemoCentryx, Inc. shares in Q3 2017, an estimated $424K.
  • Wedge Capital Management first reported a position in ChemoCentryx, Inc. in Q2 2017 and held it in 1 quarter.
  • Wedge Capital Management's ChemoCentryx, Inc. position peaked at $424K in Q2 2017.
  • 86 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q3 2017.

Based on Wedge Capital Management's 13F filing for Q3 2017, filed 31 Oct 2017.